Genome & Co. · KRX:314130
Genome & Co. financial statements
Genome & Co.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.
Financials
Annual, in KRW
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 24.6B | 27.7B | 14.3B | 14.1B | 451.2M |
| Cost of revenue | 11.2B | 12.1B | 10.2B | 8.49B | 77.0M |
| Gross profit | 13.4B | 15.7B | 4.06B | 5.60B | 374.2M |
| Research and development | 11.9B | 13.4B | 25.7B | 36.8B | 21.3B |
| Selling, general and administrative | 16.1B | 22.0B | 28.7B | 19.7B | 6.96B |
| Operating income | -29.2B | -32.6B | -57.4B | -57.5B | -36.1B |
| Depreciation and amortization | 6.67B | 4.47B | 5.31B | 4.61B | 2.59B |
| EBITDA | -22.6B | -28.1B | -52.1B | -52.9B | -33.5B |
| Interest expense | 4.72B | 3.54B | 1.74B | 175.0M | 54.9M |
| Income before tax | -8.67B | -28.2B | -51.9B | -58.0B | -36.0B |
| Net income | -6.43B | -20.1B | -47.5B | -51.8B | -34.1B |
| Earnings per share, basic | -184.22 | -647.65 | -1,611.73 | -1,839.34 | -1,212.72 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | 15.6B | 65.5B | 56.4B | 72.2B | 36.0B |
| Short-term investments | 21.2B | 11.7B | 26.1B | 29.3B | 41.1B |
| Receivables | 1.86B | 3.74B | 2.05B | 2.79B | 759.2M |
| Inventory | 5.98B | 5.77B | 3.57B | 2.24B | 1.33B |
| Current assets | 52.3B | 91.9B | 97.0B | 116.9B | 81.8B |
| Property, plant and equipment | 27.9B | 34.6B | 21.5B | ||
| Goodwill | 11.1B | 14.1B | 14.1B | 16.5B | 16.5B |
| Total assets | 145.0B | 147.3B | 162.1B | 173.0B | 137.2B |
| Accounts payable | 509.1M | 481.2M | 340.2M | 205.2M | 321.4M |
| Current liabilities | 22.8B | 29.8B | 28.2B | 11.1B | 9.83B |
| Long-term debt | 9.00B | 9.64B | |||
| Total liabilities | 30.4B | 99.0B | 99.6B | 75.7B | 23.8B |
| Shareholders' equity | 105.8B | 48.3B | 62.4B | 97.3B | 92.7B |
| Shares outstanding | 34.9M | 31.1M | 29.5M | 28.2M | 28.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash from operations | -18.4B | -7.61B | -31.0B | -36.0B | -26.2B |
| Capital spending | -497.7M | -4.19B | -19.0B | -7.28B | -3.38B |
| Free cash flow | -18.9B | -20.5B | -51.3B | -50.8B | -29.5B |
| Cash from investing | 11.6B | -15.4B | -6.38B | ||
| Cash from financing | 5.25B | 30.6B | 78.6B | ||
| Share buybacks | -54.2B | 33.8M | 81.5M | 80.2B | |
| Change in cash | -50.0B | 9.19B | -15.9B | 36.2B | -67.9B |